公开(公告)号：US20220396631A1

公开(公告)日：2022-12-15

申请号：US17595637

申请日：2020-05-19

Applicant: Lu HUANG ,  Brian GRANDA ,  John BLANKENSHIP ,  Aida ABUJOUB ,  Tony FLEMING ,  Haihui LU ,  Connie HONG ,  Brian HOLMBERG ,  Novartis AG

Inventor： Brian Walter Granda ,  John Blankenship ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  Brian Holmberg ,  Haihui Lu

IPC: C07K16/28

Abstract: The present disclosure provides multispecific binding molecules that specifically bind to BCMA, a component of a human T-cell receptor complex and either CD2 or a tumor associated antigen, conjugates comprising the multispecific binding molecules, and pharmaceutical compositions comprising the multispecific binding molecules and the conjugates The disclosure further provides methods of using the multispecific binding molecules to treat disease and disorders associated with expression of BCMA. The disclosure yet further provides recombinant host cells engineered to express the multispecific binding molecules and methods of producing the multispecific binding molecules by culturing the host cells under conditions in which the multispecific binding molecules are expressed.

公开(公告)号：US20220364055A1

公开(公告)日：2022-11-17

申请号：US17271430

申请日：2019-08-30

Applicant: Novartis AG

Inventor： Louise Treanor ,  Michael R. Greene ,  Jennifer Brogdon ,  Boris Engels ,  Glenn Dranoff ,  Olja Kodrasi ,  Hyungwook Lim ,  Akash Sohoni ,  Elizabeth Dorothy Pratico ,  Anniesha Hack ,  Aida Abujoub ,  Tony Fleming ,  Lu Huang ,  Connie Hong ,  John Blankenship ,  Brian Holmberg ,  Chonghui Zhang ,  Dexiu Bu ,  Andrew Price ,  Xu Zhu ,  Andrew Stein ,  Attilio Bondanza

IPC: C12N5/0783 ,  A61K35/17 ,  A61K31/519 ,  A61K38/20 ,  C07K16/28 ,  C07K14/705

Abstract: The invention provides methods of making immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions generated by such methods.

公开(公告)号：US20210220404A1

公开(公告)日：2021-07-22

申请号：US17104983

申请日：2020-11-25

Applicant: Michael R. Greene ,  Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Attilio Bondanza ,  Jennifer Brogdon ,  Dexiu Bu ,  Serena De Vita ,  Glenn Dranoff ,  Boris Engels ,  Tony Fleming ,  Brian Walter Granda ,  Michael R. Greene ,  Carla Patricia Guimaraes ,  Anniesha Hack ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Olja Kodrasi ,  Joni Waiee Lam ,  Hyungwook Lim ,  Elizabeth Dorothy Pratico ,  Andrew Price ,  Akash Sohoni ,  Andrew Marc Stein ,  Louise Treanor ,  Chonghui Zhang ,  Xu Zhu

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00 ,  A61K45/06 ,  A61K39/395 ,  C07K14/705 ,  A61K38/17 ,  C12N5/0783 ,  C07K14/725

Abstract: The invention provides immune effector cells (for example, T cells, NK cells) that express a chimeric antigen receptor (CAR), and compositions and methods thereof.

公开(公告)号：US11872249B2

公开(公告)日：2024-01-16

申请号：US17246351

申请日：2021-04-30

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: C07K16/28 ,  A61P35/00 ,  A61K38/17 ,  A61K39/00 ,  A61K35/17 ,  C12N15/85

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

公开(公告)号：US20230374105A1

公开(公告)日：2023-11-23

申请号：US18339565

申请日：2023-06-22

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K14/70596 ,  C07K14/7051 ,  C07K16/2803 ,  C07K16/2866 ,  A61K45/06 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001124 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2319/00 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/70 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

公开(公告)号：US20230250179A1

公开(公告)日：2023-08-10

申请号：US18170941

申请日：2023-02-17

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  A61P35/00 ,  A61K35/17 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783

CPC classification number: C07K16/2878 ,  A61P35/00 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70578 ,  C12N5/0636 ,  A61K38/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US11492409B2

公开(公告)日：2022-11-08

申请号：US16426914

申请日：2019-05-30

Applicant: NOVARTIS AG

Inventor： Aida Abujoub ,  John Blankenship ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Haihui Lu

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/46 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61K39/00

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US20220195010A1

公开(公告)日：2022-06-23

申请号：US17464528

申请日：2021-09-01

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Hans Bitter ,  Jennifer Mary Bordeaux ,  Barbara Brannetti ,  Jennifer Brogdon ,  Naveen Kumar Dakappagari ,  Saar Gill ,  Steven Highfill ,  Lu Huang ,  Carl H. June ,  Ju Young Kim ,  Ming Lei ,  Na Li ,  Andreas Loew ,  Elena Orlando ,  Marco Ruella ,  Thai Tran ,  Jimin Zhang ,  Li Zhou

IPC: C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.

公开(公告)号：US20190382500A1

公开(公告)日：2019-12-19

申请号：US16439495

申请日：2019-06-12

Applicant: Novartis AG

Inventor： Aida Abujoub ,  John Blankenship ,  Dexiu Bu ,  Tony Fleming ,  Brian Holmberg ,  Connie Hong ,  Lu Huang ,  Chonghui Zhang

IPC: C07K16/28 ,  C07K14/725 ,  C07K14/705 ,  C12N5/0783 ,  A61P35/00 ,  A61K35/17

Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA, vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

公开(公告)号：US20240252538A1

公开(公告)日：2024-08-01

申请号：US18529915

申请日：2023-12-05

Applicant: Novartis AG ,  The Trustees of the University of Pennsylvania

Inventor： Barbara Brannetti ,  Jennifer Brogdon ,  Boris Engels ,  Brian Walter Granda ,  Lu Huang ,  Ming Lei ,  Na Li ,  Jimin Zhang ,  Carla Patricia Pinto Guimaraes ,  Saar Gill ,  Marco Ruella ,  Regina M. Young

IPC: A61K35/17 ,  A61K38/17 ,  A61P35/00 ,  C07K16/28 ,  C12N15/85 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61K38/1774 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2896 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33

Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.